News
ALVO
14.40
-0.76%
-0.11
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
Alvotech is a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide. Members of management will be participating in the upcoming BofA Securities Healthcare Conference 2024. The conference will be held on May 14-15, 2024 in Las Vegas, NV.
Barchart · 4d ago
Alvotech to produce Humira biosimilar for Cigna's Quallent
Healthcare Alvotech to produce Humira biosimilar for Cigna's Quallent Pharmaceuticals. Icelandic drugmaker will manufacture a high-concentration biosimilar of AbbVie's blockbuster drug Humira. The company said the deal is in alignment with its US commercialization agreement with Teva.
Seeking Alpha · 5d ago
Alvotech: Report of foreign issuer
Press release · 5d ago
Alvotech To Manufacture Its High-concentration Interchangeable Biosimilar To Humira For Quallent
NASDAQ · 5d ago
ALVOTECH SA - STRATEGIC AGREEMENT IS IN ALIGNMENT WITH ALVOTECH'S U.S. COMMERCIALIZATION AGREEMENT WITH TEVA PHARMACEUTICALS
Reuters · 5d ago
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira (adalimumab) for Quallent Pharmaceuticals. Alvotech and Teva Pharmaceuticals entered into a strategic partnership to develop and manufacture the biosimilar in the U.S. The company's biosimilar was the first approved under the strategic partnership with Teva. The biosimilar will be the first to be approved for the high concentration of Humira and will be distributed under private label.
Barchart · 6d ago
Weekly Report: what happened at ALVO last week (0422-0426)?
Weekly Report · 6d ago
AbbVie stock slides 6% amid concerns about falling Humira sales
AbbVie stock slides 6% amid concerns about falling Humira sales. Cigna plans to offer a biosimilar of the drug's top-selling drug Humira at no cost to certain patients. Humira global sales tumbled 36% year-over-year to $2.27B.
Seeking Alpha · 04/26 18:09
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely
Alvotech has received FDA approval for its biosimilar drugs Simlandi and Selarsdi. The company will compete in the biosimilar market for Humira and Stelara. Alvotech's outlook for 2024 and 2025 is positive, with projected revenues of $300-$400 million. The Iceland-based company's stock price dropped after the FDA rejected its first biosimilar drug in 2023. Al votech's Q1 2024 earnings are expected to exceed Wall Street's expectations.
Seeking Alpha · 04/25 21:00
Analysts Are Bullish on These Healthcare Stocks: Alvotech (ALVO), Cardinal Health (CAH)
TipRanks · 04/23 10:07
Weekly Report: what happened at ALVO last week (0415-0419)?
Weekly Report · 04/22 09:48
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
Fifth Third Bancorp shares rose 4.2% to $35.67 on Friday. The company reported better-than-expected quarterly financial results. Mobile-health network Solutions shares jumped 20.2%. The Nasdaq Composite fell over 100 points in today's session.
Benzinga · 04/19 14:40
Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.
Seeking Alpha · 04/19 10:55
Alvotech Inks Long-Term Agreement With A Strategic Partner To Further Enhance Access To Adalimumab-ryvk In US Market
Teva will continue to commercialize adalimumab-ryvk under the SIMLANDI brand in the U.S. The current multi-product commercialization partnership between Teva Pharmaceuticals and Alvotech remains unchanged.  Alvotech's new partnership agreement supports Teva's financial guidance.
Benzinga · 04/19 10:11
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Alvotech announced a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. Market. The newly approved biosimilar to Humira is a high-concentration interchangeable biosimilar. Alvotech is a global biotech company specializing in the development of biosimilar medicines.
Barchart · 04/19 05:10
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Seeking Alpha · 04/17 13:26
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Alvotech (ALVO) and Pacific Biosciences (PACB)
TipRanks · 04/17 07:30
Alvotech And Teva : FDA Approves Selarsdi Injection For Psoriasis And Psoriatic Arthritis
NASDAQ · 04/17 03:10
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment
Selarsdi injection approved as a biosimilar to Stelara for the treatment of psoriasis. Selarsdi is expected to be marketed in the U.S. On or after 2025. The treatment is for patients with moderate to severe plaque Psoriasis and adults with active psoriatic arthritis.
Dow Jones · 04/16 22:04
Alvotech, Teva Announce US FDA Approval Of SELARSDI, Biosimilar To Stelara
FDA has approved SELARSDI as a biosimilar to Stelara for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. Teva is responsible for the exclusive commercialization of SELarSDI in the United States.
Benzinga · 04/16 21:33
More
Webull provides a variety of real-time ALVO stock news. You can receive the latest news about Alvotech through multiple platforms. This information may help you make smarter investment decisions.
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.